BPOM Sheds Light on Validity of Sinovac COVID-19 Vaccine

Translator:

Editor:

Markus Wisnu Murti

  • Font:
  • Ukuran Font: - +
  • An employee shows a vial of COVID-19 vaccine of Sinovac and Bio Farma at the latter's production, packaging and distribution center in Bandung, West Java, January 7, 2021. TEMPO/Prima Mulia

    An employee shows a vial of COVID-19 vaccine of Sinovac and Bio Farma at the latter's production, packaging and distribution center in Bandung, West Java, January 7, 2021. TEMPO/Prima Mulia

    TEMPO.CO, Jakarta - Food and Drug Monitoring Agency (BPOM) chairperson Penny Lukito on Monday explained about the validity of the emergency use authorization (EUA) for the Sinovac COVID-19 vaccine. 

    Lukito said the vaccine’s validity could change to a regular authorization as the BPOM received more interim data of phase 3 clinical trials. 

    “The data could increase and [the vaccine’s authorization could] change to a regular authorization, full market authorization,” said Penny in Monday’s press conference.

    Moreover, Penny said the EUA could not take effect once the pandemic status was revoked, thus the use of the vaccine must obtain proper authorization. 

    The emergency use authorization (EUA) has been issued for the COVID-19 vaccine produced by Sinovac that the government plans to use in its nationwide vaccination drive. 

    “On Monday, January 11, the BPOM approved the emergency use authorization for the COVID-19 vaccine produced by Sinovac that has worked alongside Bio Farma,” said the BPOM chairperson in the press conference. 

    Read: Indonesian Sinovac Vaccine Has 65.3 Percent Efficacy: BPOM

    FRISKI RIANA